Radiation Countermeasures: Q-3-R Alleviates Radiation-Induced Lung Inflammation and Fibrosis
Radiation exposure to lungs during nuclear catastrophes or radiotherapy poses long-term side effects and can induce pulmonary injury sufficient for ...
Radiation exposure to lungs during nuclear catastrophes or radiotherapy poses long-term side effects and can induce pulmonary injury sufficient for ...
Necessity is the mother of invention. When the U.S. Army Chemical, Biological, Radiological and Nuclear (CBRN) School’s Joint Experimentation and ...
As some 300,000 cheering race fans packed the stands at this year’s Indianapolis 500, behind the scenes an advanced network ...
NIAID’s Radiation Nuclear Countermeasures Program (RNCP) seeks support to assess current methodology and variations in radiation dosing in in vivo and in vitro studies ...
The Department of Health and Human Services and NASA have inked an interagency agreement to conduct “scientific research that would ...
Influenza pandemics, organophosphate poisoning, opioid overdose, and exposure to ionizing radiation are representative of the broad spectrum of biological, chemical, ...
Humanetics Corporation has been awarded a three-year contract valued at approximately $5.4 million from the National Institute of Allergy and ...
Boston-based cancer company Partner Therapeutics, Inc. (PTx) has acquired the global rights to develop, manufacture, and commercialize Leukine (sargramostim) from ...
In support of rapid development of safe and effective radiological/nuclear medical countermeasures for clinical use under emergency situations, the National ...
Following the October 2001 confirmation of anthrax in official government mail, a series of screening processes were implemented to safeguard ...
The Biomedical Advanced Research and Development Authority (BARDA) is soliciting proposals for the advanced research and development of medical countermeasures ...
The National Institute of Allergy and Infectious Diseases (NIAID) is soliciting study proposals to evaluate candidate cellular therapies to treat ...
The National Institute of Allergy and Infectious Diseases (NIAID) will be soliciting proposals under a new Omnibus Broad Agency Announcement ...
The Defense Threat Reduction Agency recently updated its Broad Agency Announcement (BAA) supporting Fundamental Research to Counter Weapons of Mass ...
Pluristem Therapeutics on Dec. 6 announced a milestone in its development program for PLX-R18, which is being evaluated as a ...
The U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response (ASPR) is purchasing ...
The CBRNe Summit Asia 2016 conference will be held December 5-7, 2016 in Hanoi, Vietnam. This event features stakeholder presentations ...
To help save as many people as possible in the event of a large-scale nuclear or radiological emergency, the U.S. ...
A new Department of Defense Broad Agency Announcement (BAA) released this week seeks proposals for extramural research supporting both military ...
Pluristem Therapeutics Inc., a leading developer of placenta-based cell therapy products, recently reported financial results and summarized corporate and clinical ...